Canagliflozin, an SGLT2 Inhibitor, Attenuates the Development of Hepatocellular Carcinoma in a Mouse Model of Human NASH

Scientific Reports - United Kingdom
doi 10.1038/s41598-018-19658-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Development of Hepatocellular Cancer Induced by Long Term Low Fat-High Carbohydrate Diet in a NAFLD/NASH Mouse Model

Oncotarget
Oncology
2017English

Fate and Characterization of Circulating Tumor Cells in a NOD/SCID Mouse Model of Human Hepatocellular Carcinoma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2006English

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma

Canadian Journal of Gastroenterology and Hepatology
MedicineHepatologyGastroenterology
2018English

Obesity Independently Drives NASH and Hepatocellular Carcinoma

Cancer Discovery
Oncology
2018English

Editorial: Hepatocellular Carcinoma in Non-Cirrhotic NASH-a Troubling Reality

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Recombinant Adenovirus Vector-Mediated Human MDA-7 Gene Transfection Suppresses Hepatocellular Carcinoma Growth in a Mouse Xenograft Model

Journal of Biomedical Research
BiochemistryMedicineGeneticsMolecular Biology
2012English

X-Ray Scatter Imaging of Hepatocellular Carcinoma in a Mouse Model Using Nanoparticle Contrast Agents

Scientific Reports
Multidisciplinary
2015English

Development and Validation of a Novel Immune-Related Prognostic Model in Hepatocellular Carcinoma

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Human Hepatocellular Carcinoma in a Mouse Model: Assessment of Tumor Response to Percutaneous Ablation by Using Glyceraldehyde-3-Phosphate Dehydrogenase Antagonists

Radiology
Nuclear MedicineRadiologyImaging
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy